Two Shares Head to Head: Dollar Tree, Inc. (NASDAQ:DLTR), Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

u.s stocks , earnings estimates, stock overview, earning reaction history, nasdaq, nyse

Dollar Tree, Inc. (NASDAQ:DLTR)

Dollar Tree, Inc. (NASDAQ:DLTR) closed at $114.18 on the last trading session with an increase of 1.56%, whereas, it previously closed at $112.43. The company has a market capitalization of $27.28 Billion. The company traded shares of 1.48 Million on the trading day while its three month average volume stands at 2 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Dollar Tree, Inc. (NASDAQ:DLTR) produced diluted EPS of 4.05. The EPS estimate for next year as estimated by analysts is at 6.2 while EPS for next quarter is estimated at 2.11. Earnings per Share growth for this year is reported at 151.9, while the analysts estimated the EPS growth for next year at 6.2% and Earnings growth for next 5 years stands at 11.06% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 3.7%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Dollar Tree, Inc. (NASDAQ:DLTR) is at 28.23 while the forward p/e is at 18.41. The P/S or Price to Sales ratio of Dollar Tree, Inc. (NASDAQ:DLTR) stands at 1.09 and Price to Book or P/B for the most recent quarter stands at 3.88. The Price to Free Cash Flow ratio or P/FCF is reported at 10.53. The quick ratio and the current ratio of Dollar Tree, Inc. (NASDAQ:DLTR) are reported at 0.3 and 1.3 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Dollar Tree, Inc. (NASDAQ:DLTR) stands at 4.7, 14.5 and 9.9 respectively

The trailing twelve month Revenue of Dollar Tree, Inc. (NASDAQ:DLTR) is reported at 25.06 Billion with income of 962.1 Million. The outstanding shares of Dollar Tree, Inc. (NASDAQ:DLTR) are 236.8 Million. The institutional Ownership of the shares of 91.8 stands at 0.80%, this figure is decreased -0.02 in the last six months. The insider ownership for the shares of Dollar Tree, Inc. (NASDAQ:DLTR) is ticked at 0.1%, the figure is plummeted -47.59% in the last six months.

Some other important financial aspects to be discussed here for Dollar Tree, Inc. (NASDAQ:DLTR) is the Mean Target Price estimated by the analysts which stands at 121.29. The 52 week high of Dollar Tree, Inc. (NASDAQ:DLTR) is placed at 115.45 and 52 week low is standing at 60.20.

Performance wise the shares of Dollar Tree, Inc. (NASDAQ:DLTR) rose up 6.58% for the week, it also rise 5.44% for the monthly performance, while for the quarter it went down 19.49%. The shares increase 21% for the half year and flew up for the Year-To-Date performance. The shares of Dollar Tree, Inc. (NASDAQ:DLTR) grew 25.79% for the yearly performance.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) closed at $112.32 on the last trading session with an increase of 1.83%, whereas, it previously closed at $110.3. The company has a market capitalization of $9.63 Billion. The company traded shares of 832273 on the trading day while its three month average volume stands at 922.61 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) produced diluted EPS of 0.93. The EPS estimate for next year as estimated by analysts is at 3.35 while EPS for next quarter is estimated at 0.57. Earnings per Share growth for this year is reported at 74.7, while the analysts estimated the EPS growth for next year at 3.35% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 19.9%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is at 121.03 while the forward p/e is at 33.53. The P/S or Price to Sales ratio of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands at 9.24 and Price to Book or P/B for the most recent quarter stands at 13.03. The Price to Free Cash Flow ratio or P/FCF is reported at 41.32. The quick ratio and the current ratio of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are reported at 1.9 and 1.9 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands at 6.6, 12.6 and 6 respectively

The trailing twelve month Revenue of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is reported at 1.04 Billion with income of 93.4 Million. The outstanding shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are 93.3 Million. The institutional Ownership of the shares of 99.4 stands at 0.80%, this figure is increased 1.56 in the last six months. The insider ownership for the shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is ticked at 1%, the figure is plummeted -30.8% in the last six months.

Some other important financial aspects to be discussed here for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is the Mean Target Price estimated by the analysts which stands at 123.76. The 52 week high of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is placed at 136.26 and 52 week low is standing at 72.14.

Performance wise the shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rose up 15.63% for the week, it also rise 23.1% for the monthly performance, while for the quarter it went down 10.8%. The shares decrease -14.34% for the half year and flew up for the Year-To-Date performance. The shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) grew 8.97% for the yearly performance.